Deals
Jacobio discovered JAB-23E73, which is designed to treat several KRAS mutation subtypes, and is testing the therapy in multiple Phase I trials.
FEATURED STORIES
2026 is set to be a banner year for M&A in biopharma, as buyers facing major patent cliffs fight for a small pool of late-stage assets.
Metsera showed the biopharma world that M&A is back. Who could be next?
These deals radically reshaped the biopharma world, either by one vaccine rival absorbing another, a Big Pharma doubling down after another failed acquisition or, in the case of Pfizer and Novo, two heavyweights duking it out over a hot obesity biotech.
Subscribe to BioPharm Executive
Market insights and trending stories for biopharma leaders, in your inbox every Wednesday
THE LATEST
Pioneers of synthetic biology have rallied together under the development of Senti Biosciences Inc, co-founded and led by Timothy Lu, associate professor of biological engineering, electrical engineering, and computer science at the Massachusetts Institute of Technology.
Under the terms of the deal, Sanofi is paying Amunix $1 billion up front and up to $225 million in various development milestone payments.
Going through the most newsworthy stories of the year, BioSpace found trends more than one big story, topics that just kept rising again and again. Here’s a look.
Mergers and acquisitions are part of the lifeblood of the pharmaceutical industry, as companies flex their pocketbooks to acquire pipelines and talent to bolster and complement their own programs.
The year kicked off with a bang as multiple companies raced to a public listing.
Omega raised $650 million, which it plans to invest in life science companies in the U.S. and Europe.
Shares of BeiGene have fallen 16% in China in part due to concerns over potential U.S. sanctions against Chinese biotech companies.
If successfully finalized, the transaction will give CSL access to Vifor’s pipeline of treatments for iron deficiency, kidney and cardio-renal diseases.
The deal, which could be worth as much as $12 billion USD, was also confirmed by CSL speaking to Reuters Monday morning.
BeiGene raised $3.3 billion on Shanghai’s STAR market, making it the first company to trade its shares in Shanghai, Hong Kong, and New York.